262 related articles for article (PubMed ID: 20492423)
21. Timing of dose relative to sexual intercourse attempt in previous sildenafil citrate users treated with tadalafil: a geographical comparison from a single arm, open-label study.
Rubio-Aurioles E; Glina S; Abdo CH; Hernandez-Serrano R; Rampazzo C; Sotomayor M; West TM; Gallagher GL; Lenero E
J Sex Med; 2009 Oct; 6(10):2836-50. PubMed ID: 19674256
[TBL] [Abstract][Full Text] [Related]
22. Erectile dysfunction: the Viagra revolution.
Harv Mens Health Watch; 2005 Apr; 9(9):1-6. PubMed ID: 18217258
[No Abstract] [Full Text] [Related]
23. Phosphodiesterase 5 inhibitors in vascular systemic disorders.
Allanore Y
Joint Bone Spine; 2012 Jul; 79(4):338-40. PubMed ID: 22410367
[No Abstract] [Full Text] [Related]
24. Phosphodiesterase 5 inhibition in essential hypertension.
Ghiadoni L; Versari D; Taddei S
Curr Hypertens Rep; 2008 Feb; 10(1):52-7. PubMed ID: 18367027
[TBL] [Abstract][Full Text] [Related]
25. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR
Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
[TBL] [Abstract][Full Text] [Related]
26. Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms?
Chivers ML; Rosen RC
J Sex Med; 2010 Feb; 7(2 Pt 2):858-72. PubMed ID: 19929916
[TBL] [Abstract][Full Text] [Related]
27. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
[TBL] [Abstract][Full Text] [Related]
28. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
Doggrell S
Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346
[TBL] [Abstract][Full Text] [Related]
29. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
Briganti A; Salonia A; Deho' F; Zanni G; Barbieri L; Rigatti P; Montorsi F
World J Urol; 2005 Dec; 23(6):374-84. PubMed ID: 16273417
[TBL] [Abstract][Full Text] [Related]
30. The phosphodiesterase inhibitor 'war'.
Wyllie MG
BJU Int; 2003 Apr; 91(6):573-4. PubMed ID: 12656917
[No Abstract] [Full Text] [Related]
31. The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study.
Gökçe A; Halis F; Demirtas A; Ekmekcioglu O
BJU Int; 2011 Apr; 107(8):1274-7. PubMed ID: 21929518
[TBL] [Abstract][Full Text] [Related]
32. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
[TBL] [Abstract][Full Text] [Related]
33. Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies.
Mirone V; Fusco F; Rossi A; Sicuteri R; Montorsi F
BJU Int; 2009 May; 103(9):1212-7. PubMed ID: 19154480
[TBL] [Abstract][Full Text] [Related]
34. Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates.
Chang LL; Ma M; Allmen Hv; Henderson SC; Harper K; Hornbuckle K
Curr Med Res Opin; 2010 Jun; 26(6):1451-9. PubMed ID: 20394470
[TBL] [Abstract][Full Text] [Related]
35. Vardenafil improves erectile function in men with erectile dysfunction and associated underlying conditions, irrespective of the use of concomitant medications.
Eardley I; Lee JC; Shabsigh R; Dean J; Maggi M; Neuser D; Norenberg C
J Sex Med; 2010 Jan; 7(1 Pt 1):244-55. PubMed ID: 20104672
[TBL] [Abstract][Full Text] [Related]
36. Are they better than Viagra? Two new drugs for erectile dysfunction work like Viagra and carry similar risks and benefits. Their subtle differences, however, may make a difference for some men.
Harv Health Lett; 2004 Jan; 29(3):3. PubMed ID: 14734283
[No Abstract] [Full Text] [Related]
37. Data on the utilization of treatment modalities for ED in Taiwan in the era of PDE5 inhibitors.
Tsai WK; Jiann BP
Int J Impot Res; 2014; 26(4):141-5. PubMed ID: 24451166
[TBL] [Abstract][Full Text] [Related]
38. Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study.
Fusco F; Sicuteri R; Rossi A; Kontodimas S; Haro JM; Imbimbo C; Mirone V;
Asian J Androl; 2009 Sep; 11(5):629-37. PubMed ID: 19701217
[TBL] [Abstract][Full Text] [Related]
39. Sildenafil or vardenafil nonresponders' erectile response to tadalafil.
Ozgur BC; Gonenc F; Yazicioglu AH
Urol J; 2009; 6(4):267-71. PubMed ID: 20027555
[TBL] [Abstract][Full Text] [Related]
40. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J
J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
